We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Leaves Generic Diovan Exclusivity in Ranbaxy’s Hands
Court Leaves Generic Diovan Exclusivity in Ranbaxy’s Hands
January 4, 2013
A district court threw out Mylan’s attempt to gain 180-day exclusivity for generic versions of Novartis’ high blood pressure drug Diovan on Dec. 27, saying the FDA properly granted the marketing perks to Ranbaxy.